Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 25;13(5):956. doi: 10.3390/cancers13050956

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

FOXM1- and PARP- inhibitor and carboplatin as mono- and combined therapy. Tissue was treated with thiostrepton (Thio), olaparib (Ola) and carboplatin (CP). To investigate the beneficial effect of FOXM1 inhibition, olaparib and carboplatin were combined with thiostrepton. DMSO is the vehicle control for all conditions except carboplatin. Conditions were normalized to their control, respectively. All drugs were applied for 72 h after 24 h from the start of cultivation. (A) Effect of all treatment conditions on tumor proliferation. Tissue was stained for Ki67, panCK and Hoechst to determine tumor proliferation. n = 7 (B) Effect of all treatment conditions on tumor apoptosis. Tissue was stained for cleaved PARP, panCK and Hoechst to determine tumor apoptosis. n = 7; error bars represent SEM. One-way ANOVA (p < 0.05) showed no significant alterations.